Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Resuscitation Preferences in Community Patients With Heart Failure
Redfield, Margaret M. , Mueller, Paul S. , Roger, Véronique L. , Dunlay, Shannon M. , Swetz, Keith M.

Circulation: Cardiovascular Quality and Outcomes | May 14, 2014 | Volume: 7 | Issue: 3 | Pages: 353-359

10.1161/circoutcomes.113.000759 | PMID 24823952 Get It

Background— Little is known about the resuscitation preferences of patients with heart failure, how they may change over the course of the disease, and their association with mortality. Methods and Results— We enrolled consecutive Southeastern Minnesota residents with heart failure from October 2007 through September 2011 into a longitudinal study. Information on resuscitation preferences (Full Code or do-not-resuscitate [DNR]) was obtained from medical records through April 1, 2013. Of 608 patients enrolled, 237 died during follow-up. At enrollment, most patients (73.4%) were Full Code, whereas at death, most (78.5%) were DNR. The independent predictors of DNR status at enrollment were advanced age, chronic obstructive pulmonary disease, previous malignancy, and decreased mobility. Patients who were DNR were at increased risk of death (unadjusted hazard ratio, 2.03; 95% confidence interval, 1.48–2.73; P <0.001), but this risk did not persist after adjusting for age, comorbidity, and self-perceived general health (hazard ratio, 0.97; 95% confidence interval, 0.74–1.30; P =0.83). Of 481 patients who were Full Code during follow-up, 22 (4.6%) received cardiopulmonary resuscitation for an in-hospital cardiac arrest. Eight patients survived to hospital discharge; only 2 (9.1% of those receiving cardiopulmonary resuscitation) made a complete recovery and returned home. The median time from a final decision to be DNR until death was only 37 (7,70) days. Conclusions— The resuscitation preferences of patients with heart failure seem to be driven by the decline in clinical status that often accompanies advanced age and multimorbidity. Furthermore, these data suggest that electing DNR status does not independently affect a patient’s risk of death.
Choices for Patients “Without a Choice”
Ottenberg, Abigale L., Cook, Katlyn E., Topazian, Rachel J., Mueller, Luke A. , Mueller, Paul S. , Swetz, Keith M.

Circulation: Cardiovascular Quality and Outcomes | May 14, 2014 | Volume: 7 | Issue: 3 | Pages: 368-373

10.1161/circoutcomes.113.000660 | PMID 24823955 Get It

Background— Patients undergo major physical and psychological changes after implantation of a left ventricular assist device as destination therapy (DT). We sought to qualitatively study outcomes and attitudes of patients after DT. Methods and Results— Ambulatory outpatients with DT at our institution were invited to be interviewed between June and August 2011. In-person interviews were audio-recorded, transcribed, and analyzed qualitatively using thematic analysis. The study included 12 patients (11 men) from the Midwestern United States with a median age of 71.5 years (range, 33–78 years). Interviews were conducted at a median (range) time of 1.37 (0.43–5.04) years after DT implantation. Most patients were white (n=11), married (n=10), and Christian (n=10). We identified 6 themes commonly discussed by the interviewees: preparedness planning, new lease on life, optimizing support networks, systemic limitations, reflections on time, and communication matters. Analysis revealed that most patients saw DT as their only choice, despite other alternatives. Conclusions— Ambulatory patients reported varied experiences after DT but commonly reported gratitude for improved functional status and a perception of improved symptom burden. Recommendations for improving post-DT care include developing patient support systems, systematizing education for community providers, and expanding respite services.
Robot‐assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients
Cheney, Scott, Andrews, Paul E. , Leibovich, Bradley C. , Castle, Erik P., Cheney, Scott M

BJU International | May 13, 2014 | Volume: 115 | Issue: 1 | Pages: 114-120

10.1111/bju.12804 | PMID 24825773 Get It

Objective To evaluate outcomes of the first 18 patients treated with robot‐assisted retroperitoneal lymph node dissection ( RA‐RPLND ) for non‐seminomatous germ cell tumours ( NSGCT ) and paratesticular rhabdomyosarcoma ( RMS ) at our institution. Patients and Methods Between M arch 2008 and M ay 2013, 17 patients underwent RA‐RPLND for NSGCT and one for paratesticular RMS . Data were collected retrospectively on patient demographics, preoperative tumour characteristics, and perioperative outcomes including open conversion rate, lymph node ( LN ) yield, rate of positive LNs , operative time, estimated blood loss ( EBL ), and length of stay ( LOS ). Perioperative outcomes were compared between patients receiving primary RA‐RPLND vs post‐chemotherapy RA‐RPLND . Medium‐term outcomes of tumour recurrence rate and maintenance of antegrade ejaculation were recorded. Results RA‐RPLND was completed robotically in 15 of 18 (83%) patients. LNs were positive in eight of 18 patients (44%). The mean LN yield was 22 LNs . For cases completed robotically, the mean operative time was 329 min, EBL was 103 mL, and LOS was 2.4 days. At a mean (range) follow‐up of 22 (1–58) months, there were no retroperitoneal recurrences and two of 17 (12%) patients with NSGCT had pulmonary recurrences. Antegrade ejaculation was maintained in 91% of patients with a nerve‐sparing approach. Patients receiving primary RA‐RPLND had shorter operative times compared with those post‐chemotherapy (311 vs 369 min, P = 0.03). There was no significant difference in LN yield (22 vs 18 LNs , P = 0.34), EBL (100 vs 313 mL, P = 0.13), or LOS (2.75 vs 2.2 days, P = 0.36). Conclusion This initial selected case series of RA‐RPLND shows that the procedure is safe, reproducible, and feasible for stage I – IIB NSGCT and RMS in the hands of experienced robotic surgeons. Larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.
Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
Blay, Jean‐Yves , Sobrero, Alberto , George, Suzanne , van Cutsem, Eric, Demetri, George D., Grothey, Axel , Cutsem, Eric Van , Demetri, George D. , Blay, Jean-Yves

The Oncologist | May 13, 2014 | Volume: 19 | Issue: 6 | Pages: 669-680

10.1634/theoncologist.2013-0059 | PMID 24821824 Get It

Abstract Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies. The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.
Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome
Onozawa, Masahiro , Kim, Yoo Jung , Goldberg, Liat, Bergsagel, P. Leif , Kuehl, W. Michael, Aplan, Peter D. , Bergsagel, P. Leif , Zhang, Zhenhua , Varga, Tamás

Proceedings of the National Academy of Sciences | May 13, 2014 | Volume: 111 | Issue: 21 | Pages: 7729-7734

10.1073/pnas.1321889111 | PMID 24821809 Get It

Significance We show that DNA double-strand breaks (DSBs) can be repaired by insertion of 50- to 1,000-bp sequences termed “templated-sequence insertions” (TSIs) derived from distant regions of the genome. Additional experiments indicate that the source of template for repair was primarily nuclear RNA. This mode of DNA-DSB repair by insertion is not restricted to experimentally produced breaks but also occurs at the site of spontaneous DNA DSBs in human cells. These TSIs are polymorphic in the human genome, suggesting that some TSIs occur in germ cells or embryos. Recognition of these TSIs is important in interpreting structural variations in short-read sequencing studies and provides additional polymorphic markers for population and evolution studies. This error-prone form of DNA repair may play a role in genetic diseases.
Prognostic value of a negative peak supine bicycle stress echocardiography with or without concomitant ischaemic stress electrocardiographic changes: A cohort study
Barbieri, Andréa , Mantovani, Francesca , Bursi, Francesca , Ruggerini, Sara , Lugli, R. , Modena, Maria Grazia , Abdelmoneim, Sahar S. , Mantovani, Francesca , Barbieri, Andrea , Bursi, Francesca

European Journal of Preventive Cardiology | May 13, 2014 | Volume: 22 | Issue: 5 | Pages: 636-644

10.1177/2047487314535115 | PMID 24821732 Get It

DCTN1Mutations and Progressive Supranuclear Palsy–Like Phenotype
Fujioka, Shinsuke , Tacik, Paweł , Wszołek, Zbigniew K.

JAMA Neurology | May 12, 2014 | Volume: 71 | Issue: 5 | Pages: 655

10.1001/jamaneurol.2014.227 | PMID 24818686 Get It

Faculty Opinions recommendation of Targeting and tracing of specific DNA sequences with dTALEs in living cells.
Ekker, Stephen C.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 12, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718218620.793494255 Get It

Faculty Opinions recommendation of Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.
Fernández-Zapico, Martín E.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 12, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718348656.793494314 Get It